2019 MedTech Conference in Boston

On September 23-25th, CSOFT will be attending the 2019 Medtech Conference in Boston along with 3,000 other attendees to network and share insight with medical technology industry leaders. Attendees will have the opportunity to witness more than 300 speakers discuss topics pertinent to today’s medical technology industry such as the increasing use of artificial intelligence, […]

15th CSOFT Annual Summit: Dragons, Tea, and Boats, Oh My!

Our 15th Annual Summit: Global Leaders Networking event will focus on a variety of life science industry topics. Leading executives & experts from sectors such as MedTech, pharma, and diagnostics will be hosting afternoon sessions at the Boston Public Library’s ornate Courtyard Tea Room, sharing their expertise on how to expand life science products and services internationally.

Patient communications are vital to combatting obesity

Better Patient Communications: Key to Combatting Obesity

A recent study from Duke University shows that a generic message from a doctor telling the patient to lose weight does not effect the weight loss of the patient.

Advancing The Treatment of Treatment-Resistant Depression

The FDA approved Spravato (esketamine) on March 5, 2019, as a treatment for Treatment-Resistant Depression (TRD).

Rare Disease Day: Recognizing the needs of those with rare conditions

Rare Disease Day 2019

With over 350 million patients currently diagnosed with a rare disease worldwide, what makes a rare disease ‘rare’? With the growing need for medical translations in research and patents, CSOFT bridges the gap of global healthcare.

FDA approval can be challenging, requiring expert support

First Treatment of the Rare Disease aTTP Gains FDA Approval

The FDA has approved the first treatment for the rare disease acquired Thrombotic Thrombocytopenic Purpura or aTTP for short. This rare disease occurs in less than .001% of the population and before had no cure.

FDA approved generic drugs are essential to keeping drugs affordable

First Generic Inhaler of Advair Diskus Becomes FDA Approved

On January 30, 2019, the FDA approved the first generic version of Advair Diskus. This popular inhaler medication is one of the most commonly used prescriptions for treating Asthma and Chronic Obstruction Pulmonary Disease (COPD). This new license will provide patients with access to more affordable prescriptions. This advancement will also affect the drug market in other parts of the world.

South Korea Pharmaceuticals: on the rise

The South Korea Pharmaceuticals Boom

South Korea’s economy is one of the fastest growing in the world. Pharmaceutical research in 2018 alone tripled in production compared to 2017.

CSOFT Exhibits at the DIA Annual Meeting in Boston

CSOFT International, a global leader in cross-border communications solutions, is exhibiting its life sciences business unit, MedL10N, at the DIA Annual Meeting held in Boston’s Conference and Exhibition Center from June 24 – 28, 2018.

DIA China marks its tenth anniversary with CSOFT's support

MedL10N Provides Live Interpretation Services at the 10th DIA China Annual Meeting

From May 23-25, CSOFT’s MedL10N Life Sciences Unit attended and exhibited at the 10th DIA China Conference held at the Beijing International Convention Center. This year’s event attracted thousands of pharmaceutical R&D professionals from around the world to discuss new drug regulations, drug research and development, and the future of the health care industry in China.

CFDA Reform Scheme of the Classification System for Registration of Chemical Drugs

With an aging population comes an increased demand for healthcare. Industry professionals around the world are facing increasing pressure for innovation and development of new drugs, and China is no exception.

Regulatory Submissions: FDA (US) Requirements for CDISC Standards

In addition to standards allowing easier processing and review, having information readily in a comparable format allows scientists to gather and compare study data from multiple sources. So, let’s take a quick look at those standards.